Tuberculosis infections and tumor necrosis factor alpha antagonists.
The treatment of rheumatologic diseases with tumor necrosis factor-alpha antagonists has become common practice. Studies have demonstrated an increased risk of active tuberculosis with use of tumor necrosis factor-alpha antagonists. We aim to better define the risk of tuberculosis infection associated with tumor necrosis factor-alpha antagonists and to review the literature on the treatment of latent tuberculosis.